Clinical Report: Efficacy and Safety of PD-1 Inhibitors in HIV-Positive Cancer Patients
Overview
This study evaluates the efficacy and safety of PD-1 inhibitors in HIV-positive patients with cancer.
Background
The increasing life expectancy of people living with HIV (PWH) has led to a higher incidence of noninfectious chronic diseases, particularly cancers. PWH face a significantly elevated risk of various malignancies.
Data Highlights
Parameter
HIV-Positive
HIV-Negative
Objective Response Rate (ORR)
16.2%
15.8%
Disease Control Rate (DCR)
51.4%
47.4%
Median Progression-Free Survival (PFS)
11.5 months
16.9 months
Severe Treatment-Related Adverse Events (TRAEs)
5.4%
N/A
Key Findings
The ORR and DCR were similar between HIV-positive and HIV-negative groups.
Median PFS was shorter in the HIV-positive group (11.5 months) compared to the HIV-negative group (16.9 months).
Among patients with low CD4+ T-cell counts, the DCR was 25.0%.
Severe TRAEs occurred exclusively in the HIV-positive cohort.
HIV virological control was maintained throughout the study.
Clinical Implications
Continuous monitoring of HIV status and immune function is essential during treatment.
Conclusion
Further research is warranted to validate these results.
